These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 23030485)
1. LOXL2 in epithelial cell plasticity and tumor progression. Cano A; Santamaría PG; Moreno-Bueno G Future Oncol; 2012 Sep; 8(9):1095-108. PubMed ID: 23030485 [TBL] [Abstract][Full Text] [Related]
2. Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. Moreno-Bueno G; Salvador F; Martín A; Floristán A; Cuevas EP; Santos V; Montes A; Morales S; Castilla MA; Rojo-Sebastián A; Martínez A; Hardisson D; Csiszar K; Portillo F; Peinado H; Palacios J; Cano A EMBO Mol Med; 2011 Sep; 3(9):528-44. PubMed ID: 21732535 [TBL] [Abstract][Full Text] [Related]
3. The function and mechanisms of action of LOXL2 in cancer (Review). Wu L; Zhu Y Int J Mol Med; 2015 Nov; 36(5):1200-4. PubMed ID: 26329904 [TBL] [Abstract][Full Text] [Related]
4. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment. Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405 [TBL] [Abstract][Full Text] [Related]
5. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498 [TBL] [Abstract][Full Text] [Related]
6. LOXL2 in cancer: regulation, downstream effectors and novel roles. Wen B; Xu LY; Li EM Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981 [TBL] [Abstract][Full Text] [Related]
7. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling. Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878 [TBL] [Abstract][Full Text] [Related]
8. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718 [TBL] [Abstract][Full Text] [Related]
9. LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity. Almacellas-Rabaiget O; Monaco P; Huertas-Martinez J; García-Monclús S; Chicón-Bosch M; Maqueda-Marcos S; Fabra-Heredia I; Herrero-Martín D; Rello-Varona S; de Alava E; López-Alemany R; Giangrande PH; Tirado OM Cancer Lett; 2020 Apr; 474():1-14. PubMed ID: 31911079 [TBL] [Abstract][Full Text] [Related]
10. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer. Zhu G; Wang L; Meng W; Lu S; Cao B; Liang X; He C; Hao Y; Du X; Wang X; Li L; Li L Theranostics; 2021; 11(19):9198-9216. PubMed ID: 34646366 [TBL] [Abstract][Full Text] [Related]
11. New Functions of Intracellular LOXL2: Modulation of RNA-Binding Proteins. Eraso P; Mazón MJ; Jiménez V; Pizarro-García P; Cuevas EP; Majuelos-Melguizo J; Morillo-Bernal J; Cano A; Portillo F Molecules; 2023 May; 28(11):. PubMed ID: 37298909 [TBL] [Abstract][Full Text] [Related]
12. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362 [TBL] [Abstract][Full Text] [Related]
13. Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression. Martin A; Salvador F; Moreno-Bueno G; Floristán A; Ruiz-Herguido C; Cuevas EP; Morales S; Santos V; Csiszar K; Dubus P; Haigh JJ; Bigas A; Portillo F; Cano A EMBO J; 2015 Apr; 34(8):1090-109. PubMed ID: 25759215 [TBL] [Abstract][Full Text] [Related]
14. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma. Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063 [TBL] [Abstract][Full Text] [Related]
15. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Peng DH; Ungewiss C; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Uraoka N; Mino B; Behrens C; Wistuba II; Han RI; Wanna CA; Fahrenholtz M; Grande-Allen KJ; Creighton CJ; Gibbons DL Oncogene; 2017 Apr; 36(14):1925-1938. PubMed ID: 27694892 [TBL] [Abstract][Full Text] [Related]
16. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. Hollosi P; Yakushiji JK; Fong KS; Csiszar K; Fong SF Int J Cancer; 2009 Jul; 125(2):318-27. PubMed ID: 19330836 [TBL] [Abstract][Full Text] [Related]
18. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025 [TBL] [Abstract][Full Text] [Related]
19. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition. de Jong OG; van der Waals LM; Kools FRW; Verhaar MC; van Balkom BWM J Cell Physiol; 2019 Jul; 234(7):10260-10269. PubMed ID: 30387148 [TBL] [Abstract][Full Text] [Related]
20. Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma. Sanada T; Islam A; Kaminota T; Kirino Y; Tanimoto R; Yoshimitsu H; Yano H; Mizuno Y; Okada M; Mitani S; Ugumori T; Tanaka J; Hato N Laryngoscope; 2020 May; 130(5):E327-E334. PubMed ID: 31219623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]